{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:27Z","timestamp":1794047487446,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) is a high-risk subtype of acute lymphoblastic leukemia characterized by the presence of the BCR::ABL1 fusion gene. Tyrosine kinase inhibitors (TKI) combined with chemotherapy are established as the first-line treatment. Additionally, rituximab, an anti-CD20 monoclonal antibody is administered to adult BCP-ALL patients with \u226520% CD20+ blasts. In this study, we observed a marked prevalence of CD20 expression in patients diagnosed with Ph+ BCP-ALL, indicating a potential widespread clinical application of rituximab in combination with TKI. Consequently, we examined the influence of TKI on the antitumor effectiveness of anti-CD20 monoclonal antibodies by evaluating levels of CD20 on the cell surface and conducting in vitro functional assays. All tested TKI were found to uniformly downregulate CD20 on leukemic cells, diminishing the efficacy of rituximab-mediated complement- dependent cytotoxicity. Interestingly, these TKI displayed varied effects on natural killer (NK) cell-mediated antibody- dependent cytotoxicity and macrophage phagocytic function. While asciminib demonstrated no inhibition of effector cell functions, dasatinib notably suppressed the anti-CD20-monoclonal antibody-mediated NK cell cytotoxicity and macrophage phagocytosis of BCP-ALL cells. Dasatinib and ponatinib also decreased NK cell degranulation in vitro. Importantly, oral administration of dasatinib, but not asciminib, compromised NK cell activity in patients\u2019 blood, as determined by an ex vivo degranulation assay. Our results indicate that asciminib might be preferred over other TKI for combination therapy with anti-CD20 monoclonal antibodies.<\/jats:p>","DOI":"10.3324\/haematol.2023.284853","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:37:35Z","timestamp":1717688255000},"page":"3520-3532","source":"Crossref","is-referenced-by-count":3,"title":["Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20&lt;sup&gt;+&lt;\/sup&gt; Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models"],"prefix":"10.3324","volume":"109","author":[{"given":"Krzysztof","family":"Domka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"D\u0105bkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Janowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Urba\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pastorczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Winiarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Fidyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieszko","family":"Lachota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Patkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"S\u0119dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Perkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Hunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Jakubowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Krzymieniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"M\u0142ynarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Szczepa\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Firczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"68108","doi-asserted-by":"crossref","unstructured":"Pui CH, Yang JJ, Hurgen SP. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015; 33(27):2938-2948.","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"68109","doi-asserted-by":"crossref","unstructured":"Lilljebj\u00f6rn H, Fioretos T. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 2017; 130(12):1395-1401.","DOI":"10.1182\/blood-2017-05-742643"},{"key":"68110","doi-asserted-by":"crossref","unstructured":"Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. OncoTargets Ther. 2019; 12:635-645.","DOI":"10.2147\/OTT.S189391"},{"key":"68111","doi-asserted-by":"crossref","unstructured":"Monestime S, Al Sagheer T, Tadros M. Asciminib (Scemblix): a third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation. Am J Health Syst Pharm. 2023; 80(2):36-43.","DOI":"10.1093\/ajhp\/zxac286"},{"key":"68112","doi-asserted-by":"crossref","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020; 13(1):70.","DOI":"10.1186\/s13045-020-00905-2"},{"key":"68113","doi-asserted-by":"crossref","unstructured":"Maury S, Chevret S, Thomas X. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016; 375(11):1044-1053.","DOI":"10.1056\/NEJMoa1605085"},{"key":"68114","unstructured":"National Comprehensive Cancer Network\u00ae; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Acute Lymphoblastic Leukemia Version 4. 2023."},{"key":"68115","unstructured":"National Comprehensive Cancer Network\u00ae; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Acute Lymphoblastic Leukemia Version 4. 2023."},{"key":"68116","unstructured":"Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012; 2(6):676-990."},{"key":"68117","doi-asserted-by":"crossref","unstructured":"Meyer S, Evers M, Jansen JHM. New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol. 2018; 180(6):808-820.","DOI":"10.1111\/bjh.15132"},{"key":"68118","doi-asserted-by":"crossref","unstructured":"Esteban RE, Christianne B, Alvaro A, Demichelis-G\u00f3mez R. Prognostic effect of CD20 expression in adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018; 18(5):361-367.","DOI":"10.1016\/j.clml.2018.02.013"},{"key":"68119","doi-asserted-by":"crossref","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009; 113(25):6330-6337.","DOI":"10.1182\/blood-2008-04-151860"},{"key":"68120","doi-asserted-by":"crossref","unstructured":"Jeha S, Behm F, Pei D. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006; 108(10):3302-3304.","DOI":"10.1182\/blood-2006-04-016709"},{"key":"68121","doi-asserted-by":"crossref","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506.","DOI":"10.3324\/haematol.2019.243543"},{"key":"68122","doi-asserted-by":"crossref","unstructured":"Alduailej H, Kanfar S, Bakhit K. Outcome of CD20-positive adult B-cell acute lymphoblastic leukemia and the impact of rituximab therapy. Clin Lymphoma Myeloma Leuk. 2020; 20(9):e560-e568.","DOI":"10.1016\/j.clml.2020.04.008"},{"key":"68123","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Schumich A, Printz D. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008; 112(10):3982-3988.","DOI":"10.1182\/blood-2008-06-164129"},{"key":"68124","doi-asserted-by":"crossref","unstructured":"Serbanica AN, Popa DC, Caruntu C. The significance of CD20 intensity variance in pediatric patients with B-cell precursor acute lymphoblastic leukemia. J Clin Med. 2023; 12(4):1451.","DOI":"10.3390\/jcm12041451"},{"key":"68125","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Gaipa G, Schumich A. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom. 2010; 78(3):147-153.","DOI":"10.1002\/cyto.b.20516"},{"key":"68126","doi-asserted-by":"crossref","unstructured":"Winiarska M, Bojarczuk K, Pyrzynska B. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs. 2014; 6(5):1300-1313.","DOI":"10.4161\/mabs.32106"},{"key":"68127","doi-asserted-by":"crossref","unstructured":"Schade AE, Schieven GL, Townsend R. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008; 111(3):1366-1377.","DOI":"10.1182\/blood-2007-04-084814"},{"key":"68128","doi-asserted-by":"crossref","unstructured":"Krusch M, Salih HR. Effects of BCR-ABL inhibitors on antitumor immunity. Curr Med Chem. 2011; 18(34):5174-5184.","DOI":"10.2174\/092986711798184271"},{"key":"68129","doi-asserted-by":"crossref","unstructured":"Appel S, Balabanov S, Br\u00fcmmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005; 23(8):1082-1088.","DOI":"10.1634\/stemcells.2005-0069"},{"key":"68130","doi-asserted-by":"crossref","unstructured":"Weichsel R, Dix C, Wooldridge L. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008; 14(8):2484-2491.","DOI":"10.1158\/1078-0432.CCR-07-4393"},{"key":"68131","doi-asserted-by":"crossref","unstructured":"Urba\u0144ska Z, Lejman M, Taha J. The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia. Neoplasia. 2023; 35:100840.","DOI":"10.1016\/j.neo.2022.100840"},{"key":"68132","doi-asserted-by":"crossref","unstructured":"Bobrowicz M, Dwojak M, Pyrzynska B. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017; 130(14):1628-1638.","DOI":"10.1182\/blood-2016-08-736066"},{"key":"68133","doi-asserted-by":"crossref","unstructured":"Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 2011; 16(1):277-306.","DOI":"10.2741\/3688"},{"key":"68134","doi-asserted-by":"crossref","unstructured":"Church AK, VanDerMeid KR, Baig NA. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol. 2016; 183(1):90-101.","DOI":"10.1111\/cei.12697"},{"key":"68135","doi-asserted-by":"crossref","unstructured":"Golay J, Lazzari M, Facchinetti V. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001; 98(12):3383-3389.","DOI":"10.1182\/blood.V98.12.3383"},{"key":"68136","doi-asserted-by":"crossref","unstructured":"van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006; 12(13):4027-4035.","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"68137","doi-asserted-by":"crossref","unstructured":"Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs. 2010; 2(1):14-19.","DOI":"10.4161\/mabs.2.1.10789"},{"key":"68138","doi-asserted-by":"crossref","unstructured":"Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma\/leukemia: a review of available evidence. Curr Opin Pediatr. 2008; 20(1):17-22.","DOI":"10.1097\/MOP.0b013e3282f424b0"},{"key":"68139","unstructured":"Gupta AK, Chopra A, Meena JP. Rituximab added to standard chemotherapy and its effect on minimal residual disease during induction in CD20 positive pediatric acute lymphoblastic leukemia: a pilot RCT. Am J Blood Res. 2021; 11(6):571-579."},{"key":"68140","doi-asserted-by":"crossref","unstructured":"Rodriguez-Rodriguez S, Rios Olais FA, Mora A. The impact of adding rituximab to the standard chemotherapy + TKI regimen in adults with Philadelphia-positive B acute lymphoblastic leukemia: a multicenter retrospective study. Blood. 2023; 142(Supplement 1):4204.","DOI":"10.1182\/blood-2023-186378"},{"key":"68141","doi-asserted-by":"crossref","unstructured":"Baek DW, Park HS, Sohn SK. Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study. Korean J Intern Med. 2023; 38(5):734-746.","DOI":"10.3904\/kjim.2022.401"},{"key":"68142","doi-asserted-by":"crossref","unstructured":"Gushwa NN, Kang S, Chen J, Taunton J. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. J Am Chem Soc. 2012; 134(50):20214-20217.","DOI":"10.1021\/ja310659j"},{"key":"68143","doi-asserted-by":"crossref","unstructured":"Montero JC, Seoane S, Oca\u00f1a A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011; 17(17):5546-5552.","DOI":"10.1158\/1078-0432.CCR-10-2616"},{"key":"68144","doi-asserted-by":"crossref","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019; 36(4):431-443.e5.","DOI":"10.1016\/j.ccell.2019.08.004"},{"key":"68145","doi-asserted-by":"crossref","unstructured":"Zerbit J, Tamburini J, Goldwirt L. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2021; 62(14):3558-3560.","DOI":"10.1080\/10428194.2021.1966787"},{"key":"68146","doi-asserted-by":"crossref","unstructured":"Leonard JT, Kosaka Y, Malla P. Concomitant use of a dual Src\/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 2021; 137(7):939-944.","DOI":"10.1182\/blood.2020005655"},{"key":"68147","doi-asserted-by":"crossref","unstructured":"Jabbour E, Short NJ, Jain N. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023; 10(1):e24-34.","DOI":"10.1016\/S2352-3026(22)00319-2"},{"key":"68148","doi-asserted-by":"crossref","unstructured":"Fo\u00e0 R, Bassan R, Vitale A. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020; 383(17):1613-1623.","DOI":"10.1056\/NEJMoa2016272"},{"key":"68149","doi-asserted-by":"crossref","unstructured":"Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers (Basel). 2022; 14(7):1805.","DOI":"10.3390\/cancers14071805"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284853\/77121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284853\/77698","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11637\/77121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:38Z","timestamp":1794045998000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284853","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}